AC Immune Rating Upgraded but Target Price Cut

Summary

Stocknews.com upgraded AC Immune’s (NASDAQ: ACIU) rating from ‘Hold’ to ‘Buy’. HC Wainwright also gave a ‘Buy’ rating but lowered the target price from $16.00 to $12.00. AC Immune’s stock opened at $1.63, with a 52-week range of $1.43 to $4.98. The company reported quarterly earnings per share of ($0.21), exceeding expectations. Institutional investors hold 51.36% of the stock, with notable purchases from Northern Trust Corp and Renaissance Technologies LLC.Market Beat

Impact Analysis

The event is at the company level, focusing on AC Immune’s stock rating and target price. The rating upgrade could lead to increased investor confidence and potential buying activity, while the lowered target price suggests caution regarding future growth prospects. The reported earnings beat expectations, which might positively influence stock performance. However, the stock’s 52-week low range indicates volatility and potential risk. Institutional investor activity signals a degree of confidence, potentially stabilizing the stock.Market Beat+ 2